FindTrial
Sign In

Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes inadequately controlled on diet and exercise (AMBITION 1)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525470-18-00
Enrollment
35
Registered
2026-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2026-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with type 2 diabetes

Brief summary

Change in glycated haemoglobin (HbA1c)

Detailed description

Relative change in body weight, Change in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo), Change in triglycerides, Change in non-high-density lipoprotein (non-HDL) cholesterol, Change in hsCRP, Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals), Change in systolic blood pressure

Interventions

DRUGPlacebo (Zenagamtide)
DRUGzenagamtide B 10176
DRUGNNC0487-0111 B 10143
DRUGNNC0487-0111 B 10145
DRUGNNC0487-0111 B 10144
DRUGNNC0487-0111 B 10142
DRUGNNC0487-0111 B 10141
DRUGNNC0487-0111 B 10146

Sponsors

Novo Nordisk A/S
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in glycated haemoglobin (HbA1c)—

Secondary

MeasureTime frame
Relative change in body weight, Change in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo), Change in triglycerides, Change in non-high-density lipoprotein (non-HDL) cholesterol, Change in hsCRP, Change in 7-point self-measured plasma glucose (SMPG) profiles: Mean postprandial increment (over all meals), Change in systolic blood pressure—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 27, 2026